Valuation: Annexon, Inc.

Market Cap 936M 819M 756M 705M 1.33B 88.46B 1.35B 9.07B 3.52B 43.65B 3.51B 3.44B 152B P/E 2026 *
-6.09x
P/E 2027 * -7.29x
Enterprise Value 841M 736M 680M 634M 1.19B 79.52B 1.22B 8.15B 3.16B 39.24B 3.16B 3.09B 137B EV / Sales 2026 *
-
EV / Sales 2027 * 15.7x
Free-Float
93.57%
Yield 2026 *
-
Yield 2027 * -
1 day+2.51%
1 week+8.14%
1 month+5.35%
3 months+3.07%
6 months+13.75%
Current year+13.75%
1 week 5.05
Extreme 5.05
5.73
1 month 4.46
Extreme 4.46
5.73
Current year 4.46
Extreme 4.46
7.18
1 year 1.85
Extreme 1.85
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.81
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 01/12/2014
Director of Finance/CFO 53 01/06/2019
Chief Tech/Sci/R&D Officer 68 27/07/2023
Director TitleAgeSince
Director/Board Member 58 01/12/2014
Director/Board Member 65 01/12/2014
Director/Board Member 67 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
06-11Free

Director

65,000 0.0397%
06-11Free

Director

65,000 0.0397%
06-11Free

Director

65,000 0.0397%
Change 5-day change 1-year change 3-year change Capi.($)
+2.51%+8.14%+137.92%+62.22% 913M
+3.31%-0.20%+72.71%+128.31% 55.78B
-1.32%+17.12%+79.02%+99.82% 55.66B
-1.28%+2.68%-12.60%-13.79% 23.84B
+1.79%+4.38%+5.94%+405.31% 22.7B
-1.93%+11.11%+34.89%-7.86% 18.5B
+4.45%+5.06%+36.50%-30.43% 16.12B
+0.24%+5.98%+23.45%+184.72% 13.64B
+0.14%+9.60%+33.31% - 12.95B
+1.83%+4.58%+77.42%+132.45% 12.16B
Average +0.97%+6.54%+48.86%+106.75% 23.23B
Weighted average by Cap. +0.80%+5.23%+48.83%+114.62%

Financials

2026 *2027 *
Net sales - 41M 35.89M 33.13M 30.9M 58.22M 3.88B 59.26M 397M 154M 1.91B 154M 151M 6.66B
Net income -188M -165M -152M -142M -268M -17.81B -272M -1.83B -709M -8.79B -708M -692M -30.62B -176M -154M -142M -133M -250M -16.67B -255M -1.71B -663M -8.23B -662M -648M -28.66B
Net Debt -94.47M -82.69M -76.33M -71.2M -134M -8.93B -137M -916M -355M -4.41B -355M -347M -15.36B -292M -255M -236M -220M -415M -27.6B -422M -2.83B -1.1B -13.62B -1.1B -1.07B -47.45B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
30/06/26 $5.710 +2.51% 3,633,748
29/06/26 $5.570 +1.64% 8,568,150
26/06/26 $5.480 +6.41% 14,807,062
25/06/26 $5.150 -2.83% 3,831,642
24/06/26 $5.300 +0.38% 3,303,484
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.710USD
Average target price
13.12USD
Spread / Average Target
+129.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock